Free Trial
The Market Does Not Wait. MarketBeat All Access for Just $149
Get the Deal
Claim MarketBeat All Access Sale Promotion

Sarepta Therapeutics (SRPT) Financials

Sarepta Therapeutics logo
$16.98 +0.02 (+0.11%)
As of 02:40 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare
Annual Income Statements for Sarepta Therapeutics

Annual Income Statements for Sarepta Therapeutics

This table shows Sarepta Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -220 -267 -51 -362 -715 -554 -419 -703 -536 235 -713
Consolidated Net Income / (Loss)		 -220 -267 -51 -362 -715 -554 -419 -703 -536 235 -713
Net Income / (Loss) Continuing Operations		 -220 -267 -51 -362 -715 -554 -419 -703 -536 235 -713
Total Pre-Tax Income 		-220 -267 -49 -363 -714 -553 -419 -690 -520 261 -702
Total Operating Income		 -220 -267 -172 -344 -706 -564 -460 -536 -268 218 -700
Total Gross Profit		 1.25 5.42 155 301 381 540 702 933 1,243 1,902 2,198
Total Revenue		 1.25 5.42 155 301 381 540 702 933 1,243 1,902 2,198
Operating Revenue		 1.25 5.42 155 301 381 540 702 933 1,243 1,902 2,198
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 221 272 326 645 1,086 1,104 1,162 1,469 1,511 1,684 2,898
Selling, General & Admin Expense		 75 84 123 208 285 318 283 451 482 558 492
Research & Development Expense		 146 188 167 402 734 722 771 877 877 805 1,522
Amortization Expense		 - 0.03 1.05 0.87 0.85 0.66 0.71 0.71 1.56 2.41 2.62
Other Operating Expenses / (Income)		 - 0.10 36 34 67 63 107 140 150 319 840
Restructuring Charge		 - - - - - - - - 0.00 0.00 42
Total Other Income / (Expense), net		 0.15 -0.54 123 -19 -8.32 11 41 -154 -252 43 -2.44
Interest Expense		 - - - - - 0.00 0.00 125 387 0.00 -17
Other Income / (Expense), net		 0.15 -0.54 123 -19 -8.32 11 41 -28 135 43 -19
Income Tax Expense		 - - 2.06 -0.69 1.20 1.06 -0.17 14 16 26 11
Basic Earnings per Share		 ($5.20) ($5.49) ($0.86) ($5.46) ($9.71) ($7.11) ($5.15) ($8.03) ($5.80) $2.47 ($7.13)
Weighted Average Basic Shares Outstanding		 42.29M 48.70M 58.82M 66.25M 73.62M 77.96M 81.26M 87.56M 92.40M 95.08M 100.12M
Diluted Earnings per Share		 ($5.20) ($5.49) ($0.86) ($5.46) ($9.71) ($7.11) ($5.15) ($8.03) ($5.80) $2.34 ($7.13)
Weighted Average Diluted Shares Outstanding		 42.29M 48.70M 58.82M 66.25M 73.62M 77.96M 81.26M 87.56M 92.40M 107.88M 100.12M
Weighted Average Basic & Diluted Shares Outstanding		 42.29M 48.70M 58.82M 66.25M 73.62M 77.96M 81.26M 87.98M 93.86M 97.03M 104.99M

Quarterly Income Statements for Sarepta Therapeutics

This table shows Sarepta Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -41 46 36 6.46 34 156 -448 197 -180 -283 331
Consolidated Net Income / (Loss)		 -41 46 36 6.46 34 159 -448 197 -180 -283 331
Net Income / (Loss) Continuing Operations		 -41 46 36 6.46 34 159 -448 197 -180 -283 331
Total Pre-Tax Income 		-33 40 41 14 34 172 -384 154 -194 -278 343
Total Operating Income		 -21 25 35 -0.70 22 162 -300 116 -103 -412 358
Total Gross Profit		 332 397 413 363 467 658 745 611 399 443 731
Total Revenue		 332 397 413 363 467 658 745 611 399 443 731
Operating Revenue		 332 397 413 363 467 658 745 611 399 443 731
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 353 372 379 364 445 497 1,045 496 503 855 372
Selling, General & Admin Expense		 121 132 127 139 128 164 134 138 92 128 109
Research & Development Expense		 194 196 200 180 224 200 773 204 219 325 154
Amortization Expense		 0.44 0.76 0.60 0.60 0.60 0.60 0.60 0.67 0.68 0.68 0.69
Other Operating Expenses / (Income)		 37 44 51 45 92 132 138 153 151 399 109
Total Other Income / (Expense), net		 -12 16 6.54 14 12 10 -83 38 -91 133 -15
Other Income / (Expense), net		 -12 16 6.54 14 12 10 -83 38 48 -22 -15
Income Tax Expense		 7.76 -5.28 5.33 7.12 0.40 13 64 -43 -14 4.55 12
Basic Earnings per Share		 ($0.46) $0.79 $0.38 $0.07 $0.35 $1.67 ($4.60) $2.01 ($1.80) ($2.74) $3.15
Weighted Average Basic Shares Outstanding		 88.89M 92.40M 93.99M 94.62M 95.39M 95.08M 97.36M 98.01M 100.24M 100.12M 104.99M
Diluted Earnings per Share		 ($0.46) $0.79 $0.37 $0.07 $0.34 $1.56 ($4.60) $1.89 ($1.80) ($2.62) $2.88
Weighted Average Diluted Shares Outstanding		 88.89M 92.40M 99.11M 99.14M 100.45M 107.88M 97.36M 106.62M 100.24M 100.12M 121.92M
Weighted Average Basic & Diluted Shares Outstanding		 93.55M 93.86M 94.52M 95.37M 95.52M 97.03M 98.28M 97.71M 104.79M 104.99M 105.58M

Annual Cash Flow Statements for Sarepta Therapeutics

This table details how cash moves in and out of Sarepta Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 6.75 42 477 -229 473 668 614 -1,140 -542 675 -304
Net Cash From Operating Activities		 -149 -246 -232 -389 -456 107 -443 -325 -501 -206 -205
Net Cash From Continuing Operating Activities		 -149 -246 -232 -389 -456 107 -443 -325 -501 -206 -205
Net Income / (Loss) Continuing Operations		 -220 -267 -51 -362 -715 -554 -419 -703 -536 235 -713
Consolidated Net Income / (Loss)		 -220 -267 -51 -362 -715 -554 -419 -703 -536 235 -713
Depreciation Expense		 5.25 5.61 8.09 12 25 27 38 42 44 38 45
Non-Cash Adjustments To Reconcile Net Income		 33 32 -78 77 301 81 36 418 459 49 464
Changes in Operating Assets and Liabilities, net		 32 -16 -110 -108 -67 554 -98 -82 -469 -528 -0.80
Net Cash From Investing Activities		 8.41 -90 -179 -370 287 -122 495 -1,047 -166 756 70
Net Cash From Continuing Investing Activities		 8.41 -90 -179 -370 287 -122 495 -1,047 -166 756 70
Purchase of Property, Plant & Equipment		 -3.40 -5.34 -12 -61 -60 -82 -38 -31 -76 -137 -102
Acquisitions		 -1.43 -1.53 -9.22 0.00 -173 - -2.31 -1.43 -11 -10 -7.88
Purchase of Investments		 -173 -195 -590 -1,172 -1,194 -1,334 -32 -1,938 -2,049 -1,100 -290
Divestitures		 - - 125 0.00 0.00 108 102 0.00 102 0.00 0.00
Sale and/or Maturity of Investments		 186 112 307 866 1,716 1,189 466 923 1,868 2,002 470
Net Cash From Financing Activities		 148 378 888 530 643 682 562 233 125 125 -168
Net Cash From Continuing Financing Activities		 148 378 888 530 643 682 562 233 125 125 -168
Repayment of Debt		 -3.00 -2.60 -55 -269 -0.69 0.00 0.00 -576 0.00 -0.07 -175
Repurchase of Preferred Equity		 - - - - - 0.00 0.00 -248 0.00 0.00 0.00
Repurchase of Common Equity		 - - - - - - - - 0.00 0.00 -27
Issuance of Debt		 20 - 640 236 246 291 0.00 1,127 -6.89 0.00 0.00
Issuance of Common Equity		 120 386 354 513 365 312 549 - 0.00 0.00 20
Other Financing Activities, net		 11 -5.00 -51 50 32 79 13 -71 132 125 15
Cash Interest Paid		 0.77 1.56 1.91 11 8.55 34 56 44 16 16 15
Cash Income Taxes Paid		 - - 5.34 1.55 0.93 2.51 0.58 1.70 15 23 38

Quarterly Cash Flow Statements for Sarepta Therapeutics

This table details how cash moves in and out of Sarepta Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -310 -117 -1.14 -44 -186 905 -862 270 100 188 -337
Net Cash From Operating Activities		 -115 -55 -242 15 -71 92 -583 261 -15 131 -203
Net Cash From Continuing Operating Activities		 -116 -53 -241 15 -71 92 -583 261 -15 131 -203
Net Income / (Loss) Continuing Operations		 -41 46 36 6.46 34 159 -448 197 -180 -283 331
Consolidated Net Income / (Loss)		 -41 46 36 6.46 34 159 -448 197 -180 -283 331
Depreciation Expense		 11 11 8.74 8.72 9.81 10 9.98 11 18 5.25 11
Non-Cash Adjustments To Reconcile Net Income		 75 19 -101 -13 70 94 207 1.80 174 81 86
Changes in Operating Assets and Liabilities, net		 -161 -130 -185 13 -184 -172 -353 52 -27 328 -630
Net Cash From Investing Activities		 -211 -64 219 -99 -129 764 -291 32 232 96 -134
Net Cash From Continuing Investing Activities		 -211 -64 219 -99 -129 764 -291 32 232 96 -134
Purchase of Property, Plant & Equipment		 -30 -19 -32 -29 -37 -38 -44 -32 -23 -3.59 -2.08
Acquisitions		 -11 - -10 - - - -2.24 -246 -5.31 246 -1.00
Purchase of Investments		 -646 -574 -216 -331 -389 -163 -286 241 - -246 -170
Sale and/or Maturity of Investments		 476 528 478 261 298 965 41 69 261 100 39
Net Cash From Financing Activities		 15 1.94 22 40 14 49 12 -24 -118 -39 0.24
Net Cash From Continuing Financing Activities		 15 1.94 22 40 14 49 12 -24 -118 -39 0.24
Repayment of Debt		 - - - - - - 0.00 - - -39 -250
Issuance of Debt		 - - - - - - 0.00 - - - 250
Other Financing Activities, net		 15 8.83 22 40 14 49 12 1.20 0.61 0.26 0.24
Cash Interest Paid		 7.31 0.79 7.19 0.79 7.19 0.69 7.19 - 6.77 0.95 23
Cash Income Taxes Paid		 3.58 5.51 0.91 7.08 3.62 11 0.84 19 1.16 16 1.73

Annual Balance Sheets for Sarepta Therapeutics

This table presents Sarepta Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 274 424 1,308 1,642 1,823 2,985 3,148 3,128 3,265 3,963 3,350
Total Current Assets		 225 373 1,229 1,426 1,469 2,485 2,604 2,558 2,579 3,073 2,538
Cash & Equivalents		 80 122 600 371 835 1,503 2,116 967 428 1,103 801
Short-Term Investments		 112 195 479 803 290 436 0.00 1,023 1,248 252 138
Accounts Receivable		 3.98 5.23 29 49 91 101 153 215 400 602 398
Inventories, net		 - 13 84 125 171 232 186 204 323 750 915
Prepaid Expenses		 - - - - - - - - 102 276 113
Other Current Assets		 17 27 37 78 82 213 149 150 78 90 172
Plant, Property, & Equipment, net		 37 38 43 97 130 190 191 180 227 340 345
Total Noncurrent Assets		 12 13 36 119 224 309 353 390 458 549 467
Long-Term Investments		 0.78 4.75 22 - - - - - 0.00 133 1.05
Other Noncurrent Operating Assets		 4.47 - - 107 212 295 338 390 458 416 466
Total Liabilities & Shareholders' Equity		 274 424 1,308 1,642 1,823 2,985 3,148 3,128 3,265 3,963 3,350
Total Liabilities		 83 87 519 610 1,005 2,223 2,220 2,743 2,405 2,435 2,209
Total Current Liabilities		 62 75 88 174 265 416 453 620 654 732 1,095
Short-Term Debt		 8.43 10 6.18 - - - - 0.00 105 - 0.00
Accounts Payable		 20 30 8.47 34 68 111 77 96 165 214 281
Accrued Expenses		 29 31 69 134 186 194 272 419 315 374 360
Current Deferred Revenue		 3.30 3.30 3.32 - 3.30 89 89 89 50 130 443
Other Current Liabilities		 1.28 1.31 1.39 5.77 7.84 22 15 15 18 13 11
Total Noncurrent Liabilities		 21 12 430 436 740 1,143 1,767 2,124 1,752 1,704 1,114
Long-Term Debt		 15 6.04 425 421 682 992 1,097 1,544 1,133 1,137 829
Noncurrent Deferred Revenue		 - - - - 0.00 0.00 574 485 437 325 84
Other Noncurrent Operating Liabilities		 6.17 5.95 5.54 16 58 151 96 95 182 242 201
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 190 337 789 1,032 818 762 928 385 859 1,528 1,141
Total Preferred & Common Equity		 190 337 789 1,032 818 762 928 385 859 1,528 1,141
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 190 337 789 1,032 818 762 928 385 859 1,528 1,141
Common Stock		 1,090 1,503 2,007 2,611 3,112 3,610 4,135 4,297 5,305 5,739 6,043
Retained Earnings		 -899 -1,166 -1,217 -1,579 -2,294 -2,848 -3,207 -3,910 -4,446 -4,211 -4,877
Treasury Stock		 - - - - - - - - - 0.00 -25
Accumulated Other Comprehensive Income / (Loss)		 -0.11 -0.12 -0.38 -0.10 0.05 0.00 -0.02 -1.66 0.92 -0.22 0.27

Quarterly Balance Sheets for Sarepta Therapeutics

This table presents Sarepta Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 3,156 3,060 3,126 3,110 3,224 3,424 3,600 3,465 3,680 3,493 3,179
Total Current Assets		 2,626 2,488 2,473 2,451 2,465 2,684 2,685 2,433 2,657 2,722 2,310
Cash & Equivalents		 1,039 872 852 542 427 384 198 241 511 613 464
Short-Term Investments		 1,034 1,010 1,009 1,192 963 1,077 1,001 282 290 238 189
Accounts Receivable		 202 224 237 319 379 360 435 659 527 396 395
Inventories, net		 221 203 227 244 374 486 566 941 994 1,077 1,001
Prepaid Expenses		 - - - - 239 303 321 203 208 206 73
Other Current Assets		 131 180 148 154 83 75 165 105 128 192 188
Plant, Property, & Equipment, net		 181 183 189 212 249 276 306 361 372 359 336
Total Noncurrent Assets		 349 389 464 446 510 464 609 672 651 412 533
Long-Term Investments		 - - - - - - 182 263 230 1.04 82
Other Noncurrent Operating Assets		 336 389 464 446 510 464 427 409 421 411 451
Total Liabilities & Shareholders' Equity		 3,156 3,060 3,126 3,110 3,224 3,424 3,600 3,465 3,680 3,493 3,179
Total Liabilities		 2,725 2,347 2,384 2,345 2,263 2,347 2,379 2,323 2,322 2,173 1,674
Total Current Liabilities		 603 537 499 451 609 688 699 606 920 921 499
Short-Term Debt		 - - - - 106 92 92 0.00 0.00 36 0.00
Accounts Payable		 118 107 110 88 92 107 119 156 137 94 70
Accrued Expenses		 369 346 327 322 283 350 345 392 377 296 302
Current Deferred Revenue		 89 67 45 22 112 122 127 45 395 485 116
Other Current Liabilities		 26 17 17 18 16 17 17 13 10 10 10
Total Noncurrent Liabilities		 2,122 1,810 1,886 1,895 1,654 1,659 1,679 1,717 1,402 1,252 1,175
Long-Term Debt		 1,543 1,234 1,236 1,237 1,134 1,135 1,136 1,138 1,139 1,035 838
Noncurrent Deferred Revenue		 507 485 485 485 325 325 325 325 0.00 0.00 136
Other Noncurrent Operating Liabilities		 72 91 165 173 196 199 218 254 263 217 200
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 431 713 741 764 961 1,077 1,221 1,143 1,357 1,320 1,505
Total Preferred & Common Equity		 431 713 741 764 961 1,077 1,221 1,143 1,357 1,320 1,505
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 431 713 741 764 961 1,077 1,221 1,143 1,357 1,320 1,505
Common Stock		 4,235 5,140 5,193 5,257 5,372 5,482 5,589 5,801 5,844 5,987 6,077
Retained Earnings		 -3,801 -4,427 -4,451 -4,492 -4,410 -4,404 -4,370 -4,658 -4,462 -4,642 -4,546
Treasury Stock		 - - - - - - - - -25 -25 -25
Accumulated Other Comprehensive Income / (Loss)		 -3.21 -0.42 -1.06 -0.64 -0.69 -1.03 2.25 0.03 -0.05 0.22 -0.12

Annual Metrics And Ratios for Sarepta Therapeutics

This table displays calculated financial ratios and metrics derived from Sarepta Therapeutics' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 - - - - - - - - - - 104,787,187.00
DEI Adjusted Shares Outstanding		 - - - - - - - - - - 104,787,187.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - - - -6.81
Growth Metrics		 - - - - - - - - - - -
Profitability Metrics		 - - - - - - - - - - -
Net Operating Profit after Tax (NOPAT)		 -154 -187 -120 -241 -494 -395 -322 -375 -187 197 -490
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - -19.46% -8.94% 7.38% -24.87%
Earnings before Interest and Taxes (EBIT)		 -220 -267 -49 -363 -714 -553 -419 -565 -133 261 -719
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -214 -262 -41 -358 -689 -526 -381 -523 -88 298 -675
Valuation Ratios		 - - - - - - - - - - -
Leverage & Solvency		 - - - - - - - - - - -
Liquidity Ratios		 - - - - - - - - - - -
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -121 -196 -220 -400 -590 -499 248 -406 -669 -559 -342
Efficiency Ratios		 - - - - - - - - - - -
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 9.78 20 119 279 375 479 -91 -60 421 1,177 1,029
Increase / (Decrease) in Invested Capital		 -33 9.77 100 160 96 104 -570 31 481 756 -148
Book Value per Share		 $4.20 $6.17 $12.21 $15.45 $10.98 $9.65 $10.66 $4.39 $9.19 $15.99 $10.89
Tangible Book Value per Share		 $4.06 $6.02 $11.99 $15.27 $10.81 $9.48 $10.49 $4.39 $9.19 $15.99 $10.89
Total Capital		 214 353 1,220 1,453 1,500 1,754 2,025 1,929 2,097 2,665 1,970
Total Debt		 23 16 431 421 682 992 1,097 1,544 1,238 1,137 829
Total Long-Term Debt		 15 6.04 425 421 682 992 1,097 1,544 1,133 1,137 829
Net Debt		 -181 -317 -670 -753 -443 -946 -1,019 -445 -438 -351 -112
Capital Expenditures (CapEx)		 3.40 5.34 12 61 60 82 38 31 76 137 102
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -33 -20 67 79 79 131 35 -51 355 987 503
Debt-free Net Working Capital (DFNWC)		 171 308 1,146 1,252 1,204 2,069 2,151 1,938 2,031 2,342 1,443
Net Working Capital (NWC)		 162 298 1,140 1,252 1,204 2,069 2,151 1,938 1,926 2,342 1,443
Net Nonoperating Expense (NNE)		 66 81 -69 121 221 159 97 328 349 -39 224
Net Nonoperating Obligations (NNO)		 -181 -317 -670 -753 -443 -283 -1,019 -445 -438 -351 -112
Total Depreciation and Amortization (D&A)		 5.90 5.69 7.20 4.57 25 27 38 42 44 38 45
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($5.20) ($5.49) ($0.86) ($5.46) ($9.71) ($7.11) ($5.15) ($8.03) ($5.80) $2.47 ($7.13)
Adjusted Weighted Average Basic Shares Outstanding		 45.67M 54.81M 64.98M 71.29M 77.78M 79.42M 87.15M 87.56M 92.40M 95.08M 100.12M
Adjusted Diluted Earnings per Share		 ($5.20) ($5.49) ($0.86) ($5.46) ($9.71) ($7.11) ($5.15) ($8.03) ($5.80) $2.34 ($7.13)
Adjusted Weighted Average Diluted Shares Outstanding		 45.67M 54.81M 64.98M 71.29M 77.78M 79.42M 87.15M 87.56M 92.40M 107.88M 100.12M
Adjusted Basic & Diluted Earnings per Share		 ($5.20) ($5.49) ($0.86) ($5.46) ($9.71) ($7.11) ($5.15) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 42.29M 48.70M 58.82M 66.25M 73.62M 77.96M 81.26M 87.98M 93.86M 97.03M 104.99M
Normalized Net Operating Profit after Tax (NOPAT)		 -154 -187 -120 -241 -494 -395 -322 -375 -187 197 -460
Debt Service Ratios		 - - - - - - - - - - -
Payout Ratios		 - - - - - - - - - - -

Quarterly Metrics And Ratios for Sarepta Therapeutics

This table displays calculated financial ratios and metrics derived from Sarepta Therapeutics' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 - - - - - - - - - 104,787,187.00 104,989,772.00
DEI Adjusted Shares Outstanding		 - - - - - - - - - 104,787,187.00 104,989,772.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - - -2.70 3.15
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 44.10% 53.54% 63.10% 38.93% 40.79% 65.94% 80.15% 68.38% -14.52% - -1.89%
EBITDA Growth		 81.56% 153.74% 144.00% 687.82% 296.94% 252.12% -844.22% 637.70% -184.42% - 194.71%
EBIT Growth		 74.74% 137.79% 133.06% 193.09% 202.51% 325.41% -1,025.30% 1,031.60% -263.02% - 189.48%
NOPAT Growth		 84.13% 137.24% 131.47% 99.64% 250.37% 437.67% -791.29% 44,507.27% -429.89% - 264.40%
Net Income Growth		 84.12% 141.79% 106.99% 126.98% 182.10% 248.37% -1,338.98% 2,947.86% -635.38% - 173.96%
EPS Growth		 84.35% 163.71% 106.31% 125.93% 173.91% 97.47% -1,343.24% 2,600.00% -629.41% - 162.61%
Operating Cash Flow Growth		 -76.57% 40.84% -15.61% 112.22% 38.37% 268.41% -141.01% 1,649.01% 79.37% - 65.26%
Free Cash Flow Firm Growth		 -1,273.22% -329.18% -225.75% -134.25% -104.43% -33.69% -25.34% 34.59% 30.27% - 125.94%
Invested Capital Growth		 370.62% 800.27% 1,146.91% 625.31% 299.32% 179.49% 84.61% 73.99% 44.06% - 7.59%
Revenue Q/Q Growth		 27.02% 19.58% 4.20% -12.22% 28.72% 40.94% 13.13% -17.96% -34.65% - 64.99%
EBITDA Q/Q Growth		 -486.50% 332.59% 27.36% -55.58% 96.50% 315.86% -305.02% 144.03% -122.49% - 182.56%
EBIT Q/Q Growth		 -127.45% 221.69% 47.82% -67.24% 150.47% 405.04% -323.31% 140.06% -136.08% - 179.11%
NOPAT Q/Q Growth		 84.39% 290.88% 9.23% -101.10% 6,677.39% 582.51% -240.43% 170.44% -148.86% - 219.98%
Net Income Q/Q Growth		 -71.00% 211.53% -20.89% -82.11% 420.29% 373.21% -381.36% 144.00% -191.39% - 217.01%
EPS Q/Q Growth		 -70.37% 271.74% -53.16% -81.08% 385.71% 358.82% -394.87% 141.09% -195.24% - 209.92%
Operating Cash Flow Q/Q Growth		 6.16% 52.35% -342.90% 106.17% -573.16% 230.19% -733.85% 144.79% -105.58% - -254.48%
Free Cash Flow Firm Q/Q Growth		 -22.77% -18.98% -57.56% -1.78% -7.14% 22.19% -47.72% 46.89% -14.21% - 265.81%
Invested Capital Q/Q Growth		 130.24% 57.37% 92.29% 4.10% 26.76% 10.15% 27.01% -1.89% 4.95% - 56.30%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% - 100.00%
EBITDA Margin		 -6.70% 13.04% 12.14% 6.14% 9.38% 27.67% -50.15% 26.92% -9.26% - 48.41%
Operating Margin		 -6.28% 6.21% 8.44% -0.19% 4.75% 24.56% -40.33% 18.91% -25.89% - 49.05%
EBIT Margin		 -10.00% 10.17% 10.02% 3.74% 7.28% 26.08% -51.49% 25.14% -13.88% - 46.96%
Profit (Net Income) Margin		 -12.34% 11.51% 8.74% 1.78% 7.19% 24.16% -60.08% 32.22% -45.06% - 45.29%
Tax Burden Percent		 123.40% 113.09% 87.14% 47.58% 98.84% 92.61% 116.69% 128.15% 92.73% - 96.44%
Interest Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 350.04% - 100.00%
Effective Tax Rate		 0.00% -13.09% 12.86% 52.42% 1.16% 7.39% 0.00% -28.15% 0.00% - 3.56%
Return on Invested Capital (ROIC)		 -57.60% 48.35% 23.61% -0.29% 11.53% 54.13% -54.72% 52.09% -33.55% - 66.59%
ROIC Less NNEP Spread (ROIC-NNEP)		 -52.47% 44.32% 22.18% -1.87% 7.94% 51.77% -291.32% -25.98% -357.01% - 60.12%
Return on Net Nonoperating Assets (RNNOA)		 45.06% -31.46% -10.59% 0.88% -2.60% -17.11% -27.77% 1.33% -9.34% - 10.33%
Return on Equity (ROE)		 -12.54% 16.89% 13.02% 0.60% 8.94% 37.02% -82.49% 53.42% -42.89% - 76.92%
Cash Return on Invested Capital (CROIC)		 -241.41% -158.80% -181.06% -145.51% -108.47% -69.98% -66.58% -54.07% -42.90% - -14.33%
Operating Return on Assets (OROA)		 -3.53% 3.96% 4.48% 1.72% 3.56% 13.73% -34.38% 17.56% -9.45% - 30.87%
Return on Assets (ROA)		 -4.35% 4.48% 3.90% 0.82% 3.52% 12.71% -40.12% 22.51% -30.67% - 29.77%
Return on Common Equity (ROCE)		 -12.54% 16.89% 13.02% 0.60% 8.94% 37.02% -82.49% 53.42% -42.89% - 76.92%
Return on Equity Simple (ROE_SIMPLE)		 -90.39% 0.00% 1.76% 4.39% 9.98% 0.00% -21.74% 0.00% 0.00% - 0.00%
Net Operating Profit after Tax (NOPAT)		 -15 28 30 -0.33 22 150 -210 148 -72 -288 346
NOPAT Margin		 -4.40% 7.02% 7.36% -0.09% 4.70% 22.74% -28.23% 24.24% -18.12% - 47.30%
Net Nonoperating Expense Percent (NNEP)		 -5.13% 4.03% 1.43% 1.58% 3.60% 2.36% 236.60% 78.06% 323.46% - 6.47%
Return On Investment Capital (ROIC_SIMPLE)		 - 1.33% - - - 5.62% -9.22% 5.93% -3.03% -14.63% 14.75%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
SG&A Expenses to Revenue		 36.43% 33.19% 30.72% 38.24% 27.44% 24.89% 17.94% 22.57% 23.01% - 14.91%
R&D to Revenue		 58.56% 49.28% 48.47% 49.51% 48.05% 30.37% 103.84% 33.45% 54.81% - 21.07%
Operating Expenses to Revenue		 106.28% 93.79% 91.56% 100.19% 95.25% 75.44% 140.33% 81.09% 125.89% - 50.95%
Earnings before Interest and Taxes (EBIT)		 -33 40 41 14 34 172 -384 154 -55 -434 343
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -22 52 50 22 44 182 -374 164 -37 -429 354
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 14.79 10.50 12.60 13.87 9.75 7.60 5.42 1.24 1.43 - 1.52
Price to Tangible Book Value (P/TBV)		 14.79 10.50 12.60 13.87 9.75 7.60 5.42 1.24 1.43 - 1.52
Price to Revenue (P/Rev)		 10.23 7.26 8.63 9.92 7.26 6.11 2.77 0.68 0.78 - 1.05
Price to Earnings (P/E)		 0.00 0.00 716.73 313.79 95.28 49.37 0.00 0.00 0.00 - 35.12
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Earnings Yield		 0.00% 0.00% 0.14% 0.32% 1.05% 2.03% 0.00% 0.00% 0.00% - 2.85%
Enterprise Value to Invested Capital (EV/IC)		 40.40 20.38 14.77 17.44 11.00 9.57 4.38 1.22 1.37 - 1.48
Enterprise Value to Revenue (EV/Rev)		 9.78 6.90 8.52 9.77 7.17 5.92 2.93 0.72 0.87 - 1.09
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 157.57 144.14 69.97 37.73 0.00 105.60 0.00 - 45.27
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 351.12 236.26 90.86 43.19 0.00 0.00 0.00 - 313.95
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 509.11 154.11 57.25 0.00 0.00 0.00 - 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 13.62
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 1.62 1.44 1.29 1.14 1.01 0.74 1.00 0.84 0.81 - 0.56
Long-Term Debt to Equity		 1.62 1.32 1.18 1.05 0.93 0.74 1.00 0.84 0.78 - 0.56
Financial Leverage		 -0.86 -0.71 -0.48 -0.47 -0.33 -0.33 0.10 -0.05 0.03 - 0.17
Leverage Ratio		 5.24 5.14 3.75 3.60 3.38 3.03 3.18 2.92 2.79 - 2.51
Compound Leverage Factor		 5.24 5.14 3.75 3.60 3.38 3.03 3.18 2.92 9.77 - 2.51
Debt to Total Capital		 61.80% 59.03% 56.32% 53.24% 50.13% 42.67% 49.90% 45.64% 44.79% - 35.77%
Short-Term Debt to Total Capital		 0.00% 5.03% 4.80% 3.97% 3.74% 0.00% 0.00% 0.00% 1.51% - 0.00%
Long-Term Debt to Total Capital		 61.80% 54.00% 51.52% 49.27% 46.39% 42.67% 49.90% 45.64% 43.29% - 35.77%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Common Equity to Total Capital		 38.20% 40.97% 43.68% 46.76% 49.87% 57.33% 50.10% 54.36% 55.21% - 64.23%
Debt to EBITDA		 -3.48 -14.01 16.33 12.02 7.31 3.81 -9.09 67.23 -16.78 - 15.89
Net Debt to EBITDA		 1.40 4.96 -2.00 -2.30 -0.91 -1.18 -2.81 6.44 -3.43 - 1.95
Long-Term Debt to EBITDA		 -3.48 -12.82 14.94 11.13 6.76 3.81 -9.09 67.23 -16.21 - 15.89
Debt to NOPAT		 -4.42 -6.60 -26.34 42.47 16.09 5.78 -13.87 -1,746.56 -12.09 - -7.70
Net Debt to NOPAT		 1.78 2.34 3.22 -8.11 -2.00 -1.78 -4.29 -167.37 -2.47 - -0.95
Long-Term Debt to NOPAT		 -4.42 -6.04 -24.10 39.30 14.89 5.78 -13.87 -1,746.56 -11.69 - -7.70
Altman Z-Score		 1.96 1.47 2.46 3.17 2.45 2.71 0.63 0.12 -0.08 - 0.54
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 5.44 3.95 4.05 3.90 3.84 4.20 4.02 2.89 2.95 - 4.63
Quick Ratio		 4.55 3.18 2.91 2.64 2.33 2.67 1.95 1.44 1.35 - 2.10
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -381 -453 -714 -727 -779 -606 -895 -476 -543 -140 232
Operating Cash Flow to CapEx		 -386.57% -287.08% -746.13% 51.23% -189.73% 241.70% -1,336.59% 821.92% -63.60% - -9,739.69%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -3.92 - 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.11 - 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.27 - 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.35 0.39 0.45 0.46 0.49 0.53 0.67 0.70 0.68 - 0.66
Accounts Receivable Turnover		 4.25 4.04 4.66 5.04 4.35 3.80 4.30 5.59 5.81 - 4.14
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Fixed Asset Turnover		 5.62 6.11 6.49 6.47 6.33 6.70 7.32 7.66 7.26 - 6.27
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Days Sales Outstanding (DSO)		 85.94 90.26 78.37 72.37 83.82 96.17 84.83 65.25 62.78 - 88.08
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Cash Conversion Cycle (CCC)		 85.94 90.26 78.37 72.37 83.82 96.17 84.83 65.25 62.78 - 88.08
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 268 421 810 843 1,068 1,177 1,495 1,467 1,539 1,029 1,608
Invested Capital Turnover		 13.10 6.89 3.21 3.14 2.46 2.38 1.94 2.15 1.85 - 1.41
Increase / (Decrease) in Invested Capital		 366 481 745 727 801 756 685 624 471 -148 113
Enterprise Value (EV)		 10,810 8,582 11,959 14,701 11,758 11,263 6,545 1,790 2,102 - 2,388
Market Capitalization		 11,307 9,021 12,111 14,935 11,910 11,614 6,193 1,681 1,883 - 2,285
Book Value per Share		 $8.19 $9.19 $10.23 $11.39 $12.80 $15.99 $11.78 $13.81 $13.51 $10.89 $14.34
Tangible Book Value per Share		 $8.19 $9.19 $10.23 $11.39 $12.80 $15.99 $11.78 $13.81 $13.51 $10.89 $14.34
Total Capital		 2,001 2,097 2,200 2,303 2,449 2,665 2,281 2,497 2,391 1,970 2,343
Total Debt		 1,237 1,238 1,239 1,226 1,228 1,137 1,138 1,139 1,071 829 838
Total Long-Term Debt		 1,237 1,133 1,134 1,135 1,136 1,137 1,138 1,139 1,035 829 838
Net Debt		 -497 -438 -151 -234 -153 -351 352 109 219 -112 103
Capital Expenditures (CapEx)		 30 19 32 29 37 38 44 32 23 3.59 2.08
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 267 355 571 626 879 987 1,304 937 986 503 1,158
Debt-free Net Working Capital (DFNWC)		 2,000 2,031 1,962 2,087 2,077 2,342 1,827 1,737 1,837 1,443 1,811
Net Working Capital (NWC)		 2,000 1,926 1,856 1,995 1,986 2,342 1,827 1,737 1,801 1,443 1,811
Net Nonoperating Expense (NNE)		 26 -18 -5.70 -6.79 -12 -9.32 237 -49 108 -5.26 15
Net Nonoperating Obligations (NNO)		 -497 -438 -151 -234 -153 -351 352 109 219 -112 103
Total Depreciation and Amortization (D&A)		 11 11 8.74 8.72 9.81 10 9.98 11 18 5.25 11
Debt-free, Cash-free Net Working Capital to Revenue		 24.12% 28.54% 40.69% 41.61% 53.59% 51.89% 58.40% 37.75% 40.85% - 53.00%
Debt-free Net Working Capital to Revenue		 181.01% 163.36% 139.79% 138.65% 126.65% 123.12% 81.80% 70.00% 76.10% - 82.90%
Net Working Capital to Revenue		 181.01% 154.88% 132.27% 132.57% 121.06% 123.12% 81.80% 70.00% 74.61% - 82.90%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.46) $0.79 $0.38 $0.07 $0.35 $1.67 ($4.60) $2.01 ($1.80) ($2.74) $3.15
Adjusted Weighted Average Basic Shares Outstanding		 88.89M 92.40M 93.99M 94.62M 95.39M 95.08M 97.36M 98.01M 100.24M 100.12M 104.99M
Adjusted Diluted Earnings per Share		 ($0.46) $0.79 $0.37 $0.07 $0.34 $1.56 ($4.60) $1.89 ($1.80) ($2.62) $2.88
Adjusted Weighted Average Diluted Shares Outstanding		 88.89M 92.40M 99.11M 99.14M 100.45M 107.88M 97.36M 106.62M 100.24M 100.12M 121.92M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 93.55M 93.86M 94.52M 95.37M 95.52M 97.03M 98.28M 97.71M 104.79M 104.99M 105.58M
Normalized Net Operating Profit after Tax (NOPAT)		 -15 17 30 -0.49 22 150 -210 81 -44 -288 346
Normalized NOPAT Margin		 -4.40% 4.34% 7.36% -0.14% 4.70% 22.74% -28.23% 13.24% -11.02% - 47.30%
Pre Tax Income Margin		 -10.00% 10.17% 10.02% 3.74% 7.28% 26.08% -51.49% 25.14% -48.59% - 46.96%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.40 - 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.52 - 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.57 - 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.69 - 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%

Financials Breakdown Chart

Key Financial Trends

Here is MarketBeat’s quick take on Sarepta Therapeutics (SRPT) using the last four years of quarterly data. Key themes include a notable revenue lift in 2024, continued profitability swings in 2025, and a reasonably strong cash position that supports liquidity despite ongoing operating losses in several quarters.

  • 2024 Q4 revenue rose to about $658.4 million, up from $396.8 million in 2023 Q4 (clear year-over-year top-line growth).
  • 2024 Q4 consolidated net income was about $159.0 million, signaling a profitable quarter after a stretch of smaller or negative results.
  • 2025 Q2 revenue was $611.1 million, up from 2024 Q2’s $362.9 million, indicating continued top-line expansion into mid-2025.
  • 2025 Q2 net income from continuing operations was about $196.9 million, a positive quarterly contribution despite a volatile earnings backdrop.
  • As of 2025 Q4, Sarepta’s cash and equivalents were roughly $613 million, contributing to a solid liquidity position.
  • Long-term debt remained in a similar range across 2024–2025 (roughly around $1.0B+, based on 2025 quarterly balances), suggesting a relatively stable leverage profile.
  • Inventory and accounts receivable levels rose in several quarters (e.g., inventories around $1.08B and accounts receivable near $396M in 2025 Q3), indicating higher working capital needs as revenue grows.
  • 2025 Q4 net income attributable to common shareholders was -$282.8 million, highlighting continued quarterly losses despite revenue.
  • 2025 Q1 net income was -$447.5 million, underscoring ongoing profitability challenges during the year.
  • 2025 Q4 total operating expenses were about $854.5 million, a substantial expense load relative to revenue (driving the quarterly loss).
05/22/26 02:40 PM ETAI Generated. May Contain Errors.

Sarepta Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Sarepta Therapeutics' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Sarepta Therapeutics' net income appears to be on an upward trend, with a most recent value of -$713.41 million in 2025, rising from -$220.03 million in 2015. The previous period was $235.24 million in 2024. See Sarepta Therapeutics' forecast for analyst expectations on what's next for the company.

Sarepta Therapeutics' total operating income in 2025 was -$699.78 million, based on the following breakdown:
  • Total Gross Profit: $2.20 billion
  • Total Operating Expenses: $2.90 billion

Over the last 10 years, Sarepta Therapeutics' total revenue changed from $1.25 million in 2015 to $2.20 billion in 2025, a change of 175,337.9%.

Sarepta Therapeutics' total liabilities were at $2.21 billion at the end of 2025, a 9.3% decrease from 2024, and a 2,547.7% increase since 2015.

In the past 10 years, Sarepta Therapeutics' cash and equivalents has ranged from $80.30 million in 2015 to $2.12 billion in 2021, and is currently $801.28 million as of their latest financial filing in 2025.

Over the last 10 years, Sarepta Therapeutics' book value per share changed from 4.20 in 2015 to 10.89 in 2025, a change of 158.9%.


Related Companies

Financial statements for NASDAQ:SRPT last updated on 5/8/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
The SpaceX supplier that shipped 5 billion chips to Starlink
When Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...
Weiss Ratings | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
A letter from Shannon Stansberry
Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...
Porter & Company | Sponsoredtc pixel
Goldman Sachs just told you what to buy (most people missed it)
Goldman Sachs just revealed that 40% of AI data centers will be crippled by electricity shortages by 2027 - no...
Behind the Markets | Sponsoredtc pixel
Maybe the Greatest Strategy of the Decade
Nate Bear, Lead Technical Tactician at Monument Traders Alliance, is going public with his highest-conviction ...
Monument Traders Alliance | Sponsoredtc pixel
NEW LAW: Congress Approves Setup For Digital Dollar?
On July 17th, the House passed the GENIUS Act - and at least one prominent Trump ally is raising alarms. Rep. ...
Goldco Direct, LLC | Sponsoredtc pixel
To Avoid 67 Million Blackouts, Trump Signs Emergency Backing of New Energy Tech
President Trump has used emergency executive powers to back a new energy technology described as 326 times mor...
Altimetry | Sponsoredtc pixel
"Computers are about to become obsolete" - George Gilder. Here’s why.
George Gilder predicted the iPhone 16 years early, called Netflix a decade before it dominated streaming, and ...
Eagle Publishing | Sponsoredtc pixel